Clinical trial NCT06921317: GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma
Official title: Proof of Concept Clinical Trial of Gene Therapy GVB-2001 Delivered Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE1
PHASE2
Conditions: Primary Open-Angle Glaucoma (POAG)
Keywords: glaucoma
gene therapy
rho gene
trabecular meshwork
dnRhoA
IOP reduction
AAV
scAAV
Lead sponsor: IVIEW Therapeutics Inc.
Sponsor class: INDUSTRY
Collaborators: name: The First Affiliated Hospital of Soochow University
First posted: 2025-04-10
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This is an investigator initiated, single center, open label, non-randomized, exploratory clinical study. The purpose is to assess the safety and preliminary efficacy of gene therapy GVB-2001 (ScAAV2-dnRhoA) delivered via intracameral injection to the anterior segment of the eye for the treatment of subjects with primary open-angle glaucoma. At least 12 primary open angle glaucoma (POAG) patients with high intraocular pressure (IOP) will be divided into two experimental groups. Each experimental group will be given low dose or high dose of the gene injection treatment, respectively. The optimal dose will be selected based on the trial results for future development of GVB-2001.

Safety Review Committee, SRC will be set up for safety assessment of the study. The study subjects included will be 18 to 65 years of age (inclusion) and are diagnosed with primary open-angle glaucoma (POAG) for 1 year or more. Participants were screened and provided informed consent during screening and will be enrolled into the trial.

Detailed description: This research plans to recruit at least 12 high intraocular pressure of primary open-angle glaucoma (POAG) patients in one clinical center and divide into two groups. Six primary glaucoma (POAG) patients with elevated intraocular pressure and no vision in the target eye were enrolled in trial group 1. They will be divided into two dose groups: low-dose group (n = 3) and high-dose group (n = 3). The safety review committee (SRC) will determine whether to enter the high- dose group after the last subject in the low-dose group has completed the Dose limited toxicity (DLT) assessment. In group 2, 6 primary open-angle (POAG) patients with normal visual acuity and high intraocular pressure will be enrolled. The patients will be divided into low-dose group (3 subjects) and high-dose group (3 subjects). The safety review committee (SRC) will determine whether to enter the low-dose group of trial group 2, and whether to enter the high-dose group of trial group 2, after the completion of the evaluation of DLT in the low-dose group of trial group 1. During the study of trial group 2, the safety review committee (SRC) will determine whether to add another optimized dose group to trial group 2, and determine the optimized therapeutic dose and the number of subjects in the optimized dose group.

Eligibility criteria: Inclusion Criteria:

1. The subjects volunteered to participate in the clinical study and signed written informed consent;
2. Aged 18 to 65 years old (inclusive), men and women;
3. Primary open angle glaucoma (POAG) with a history of diagnosis ≥1 year;
4. Participants in good general health and have no clinically significant systemic disease, as determined by medical history, physical examination, and screening laboratory evaluation.
5. To comply with the requirements, willing to accept all the diagnosis and treatment plan, laboratory tests and other specified testing, etc.;
6. Consent is obtained for an extended safety visit after 1 year.

Special eligibility criteria for trial group 1:

1. no vision in the target eye;
2. The intraocular pressure (IOP) of the target eye was ≤40mmHg and \> 21 mmHg after combined treatment with 2 or more IOP-lowering drugs.

Special inclusion criteria for trial group 2:

1. The intraocular pressure (IOP) of the target intervention eye was no more than 30mmHg, and the IOP was more than 21 mmHg after receiving combination therapy of 2 or more IOP-lowering drugs;
2. The Shaffer gonioscopy scores of the target intervention eyes were all greater than 3.
3. The best corrected distance visual acuity of the target intervention eyes was at least 0.8 (logMAR4.9) and above.

Exclusion Criteria:

1. Secondary glaucoma;
2. Any active or recurrent intraocular infection or inflammation, including but not limited to uveitis;
3. Severe dry eye or clinically significant active keratopathy in the target eye;
4. No intraocular pressure measurement was performed under any circumstances;
5. Allergies to drugs or their excipient to be used in clinical studies;
6. The target eye had undergone intraocular anti-glaucoma surgery or anti- glaucoma laser surgery;
7. Ocular trauma in either eye within 6 months before screening, or eye surgery or nonrefractive laser therapy within 3 months before screening;
8. A clinically significant history of herpes simplex or herpes zoster keratitis;
9. A positive test for hepatitis B virus (HBV) HBsAg or HBV-DNA, hepatitis C virus (HCV) HCAb, or Epstein-Barr virus, or cytomegalovirus (CMV);
10. Syphilis antibody and HIV antibody were positive.
11. The serum Anti-AAV2 neutralizing antibody titer was \> 1:600 at the time of screening.
12. Severe active systemic bacterial, viral, fungal, malaria, or parasitic infections;
13. Any past or present malignant tumor, myeloproliferative disorder or immunodeficiency disease;
14. May interfere with the clinical significance of this study of systemic disease (including, active hepatitis, liver cirrhosis, liver fibrosis uncontrolled hypertension, myocardial infarction and myocarditis, arrhythmia, stroke, acute or chronic renal insufficiency, uncontrolled endocrine system diseases such as diabetes, thyroid function hyperfunction, Severe pulmonary hypertension, chronic obstructive pulmonary disease (copd), interstitial pneumonia, etc.);
15. Any serious mental illness;
16. Have participated in other clinical trials and received a medication or medical device intervention within 1 month before screening;
17. And women of childbearing age who are pregnant, breastfeeding, planning to become pregnant, or who are not using a medically acceptable form of birth control. Excludes women of childbearing age who have been sterilized for 1 year after menopause or 3 months after surgery;
18. Other subjects judged by the clinical investigator to be ineligible for inclusion.

Special Exclusion Criteria for trial group 2:

1. Retinal diseases that might have interfering with the study: quadrantinal blindness of unknown cause, wet age-related macular degeneration, retinal vein occlusion, cystoid macular edema, macular hole, maculopathy with neovascularization, and central serous retinopathy;
2. Narrow anterior chamber Angle, congenital Angle closure glaucoma or room, clinically significant peripheral anterior chamber adhesion or anterior chamber Angle surgery/laser treatment cause extensive catarrhal adhesion of history;
3. The central corneal thickness was less than 480μm or more than 620μm.
4. Presence of severe visual field impairment (e.g., mean deviation less than -12 dB or mean visual field defect greater than 2 dB/ year, as assessed by a perimetry analyzer)

Primary outcomes:
measure: The number and proportion of subjects with IOP ≤21mmHg
timeFrame: Day 28, Day 60, Day 90, 6-Month, and 12-Month after GVB-2001 administration.
measure: The number and proportion of subjects whose IOP decreased by ≥20% from baseline
timeFrame: Day 28, Day 60, Day 90, 6-Month, and 12-Month after GVB-2001 administration.
measure: Ocular adverse events (AEs) : the characteristics of AES, including endophthalmitis, eyelid edema, and corneal injection site reaction
timeFrame: Day 1, Day 3, Day 7, Day 14, Day 28, Day 60, Day 90, 6-Month and 12--Month after GVB-2001 administration.
Secondary outcomes:
measure: Type, number, and incidence of systemic adverse events and serious adverse events
timeFrame: Adverse events (AEs): The type, number and incidence of AEs and serious adverse events (SAEs) will be analysized within 12 months after GVB-2001 administration.
measure: No ocular malignancies related to GVB-2001 injection occurred after treatment
timeFrame: After GVB-2001 Administration up to 5 years.
measure: RhoA protein concentration in blood
timeFrame: Day 7, Day 28, and 12-Month after GVB-2001 administration
measure: RhoA protein concentration in urine
timeFrame: Day 7, Day 28, and 12-Month after GVB-2001 administration
measure: RhoA protein concentration in tears
timeFrame: Day 7, Day 28, and 12-Month after GVB-2001 administration
measure: AAV2 Virus Shedding in blood
timeFrame: Day 7, Day 28, and Month 12 after GVB-2001 administration
measure: AAV2 Virus Shedding in urine
timeFrame: Day 7, Day 28, and 12-Month after GVB-2001 administration
measure: AAV2 Virus Shedding in tears
timeFrame: Day 7, Day 28, and 12-Month after GVB-2001 administration
measure: Humoral immunity response
timeFrame: Day 7, Day 28, and 12-Month after GVB-2001 administration
measure: Cellular immunity response
timeFrame: Day 7, Day 28, and 12-Month after GVB-2001 administration
measure: AAV2 antibody titer level in blood
timeFrame: Day 7, Day 28, and 12-Month after GVB-2001 administration.
measure: The supervision evaluation Dose limiting toxicity (dosed limited toxicity DLT) happening
timeFrame: Day 28 after GVB-2001 administration.
Other outcomes:
Locations:
city: Suzhou
country: China
facility: The First Affiliated Hospital of Soochow University
state: Jiangsu
Study officials:
affiliation: The First Affiliated Hospital of Soochow University
name: Peirong Lu, MD
role: PRINCIPAL_INVESTIGATOR
References: